Astrazeneca PLC (AZN) PT Set at $38.00 by BMO Capital Markets

Astrazeneca PLC (NYSE:AZN) has been assigned a $38.00 price objective by analysts at BMO Capital Markets in a research note issued to investors on Tuesday. The firm currently has a “buy” rating on the stock. BMO Capital Markets’ price objective would indicate a potential upside of 10.14% from the company’s previous close.

A number of other research analysts also recently issued reports on AZN. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Astrazeneca PLC in a report on Wednesday, August 9th. BidaskClub downgraded Astrazeneca PLC from a “sell” rating to a “strong sell” rating in a report on Friday, August 4th. Leerink Swann upped their price target on Astrazeneca PLC from $31.00 to $34.00 and gave the company a “market perform” rating in a report on Monday, October 23rd. Cowen and Company reaffirmed a “hold” rating and set a $37.00 price target on shares of Astrazeneca PLC in a report on Tuesday, October 17th. Finally, Credit Suisse Group raised Astrazeneca PLC from a “neutral” rating to an “outperform” rating in a report on Monday, October 16th. Four analysts have rated the stock with a sell rating, ten have issued a hold rating and fifteen have assigned a buy rating to the company’s stock. Astrazeneca PLC has an average rating of “Hold” and an average price target of $35.10.

TRADEMARK VIOLATION NOTICE: “Astrazeneca PLC (AZN) PT Set at $38.00 by BMO Capital Markets” was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.com-unik.info/2017/11/02/astrazeneca-plc-azn-pt-set-at-38-00-by-bmo-capital-markets.html.

Several large investors have recently added to or reduced their stakes in the stock. Fisher Asset Management LLC grew its position in shares of Astrazeneca PLC by 4.7% during the third quarter. Fisher Asset Management LLC now owns 11,601,573 shares of the company’s stock worth $393,061,000 after purchasing an additional 519,717 shares in the last quarter. BlackRock Inc. grew its position in shares of Astrazeneca PLC by 287,844.0% during the first quarter. BlackRock Inc. now owns 6,910,657 shares of the company’s stock worth $215,198,000 after purchasing an additional 6,908,257 shares in the last quarter. Federated Investors Inc. PA grew its position in shares of Astrazeneca PLC by 3.6% during the second quarter. Federated Investors Inc. PA now owns 4,484,770 shares of the company’s stock worth $152,885,000 after purchasing an additional 156,256 shares in the last quarter. Ameriprise Financial Inc. grew its position in shares of Astrazeneca PLC by 5.9% during the second quarter. Ameriprise Financial Inc. now owns 2,827,262 shares of the company’s stock worth $96,789,000 after purchasing an additional 157,293 shares in the last quarter. Finally, Voya Investment Management LLC grew its position in shares of Astrazeneca PLC by 38.2% during the second quarter. Voya Investment Management LLC now owns 2,395,465 shares of the company’s stock worth $81,661,000 after purchasing an additional 662,481 shares in the last quarter. Hedge funds and other institutional investors own 14.18% of the company’s stock.

About Astrazeneca PLC

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for Astrazeneca PLC (NYSE:AZN)

What are top analysts saying about Astrazeneca PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Astrazeneca PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit